Published in Br J Clin Pharmacol on October 01, 2011
Dual Antiplatelet Therapy Tailored on the Extent of Platelet Inhibition (DANTE) | NCT00774475
Personalized medicine: is it a pharmacogenetic mirage? Br J Clin Pharmacol (2012) 1.44
Addressing phenoconversion: the Achilles' heel of personalized medicine. Br J Clin Pharmacol (2015) 0.90
Optimizing clopidogrel dose response: a new clinical algorithm comprising CYP2C19 pharmacogenetics and drug interactions. Ther Clin Risk Manag (2015) 0.80
The role of pharmacogenetics in nonmalignant gastrointestinal diseases. Nat Rev Gastroenterol Hepatol (2012) 0.79
Cytochrome P450 2C19 Polymorphism in Iranian Patients with Coronary Artery Disease. ARYA Atheroscler (2011) 0.78
Pharmacogenomics of Drug Metabolizing Enzymes and Transporters: Relevance to Precision Medicine. Genomics Proteomics Bioinformatics (2016) 0.76
Potent and Orally Bioavailable Antiplatelet Agent, PLD-301, with the Potential of Overcoming Clopidogrel Resistance. Lett Drug Des Discov (2016) 0.76
Snapshot of the prescribing practice for the clopidogrel and esomeprazole coprescription and cost evaluation of the application guidelines. Pharmacol Res Perspect (2016) 0.75
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med (2001) 20.20
Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med (2007) 17.85
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet (1996) 16.32
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA (2002) 11.06
Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med (2008) 9.25
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet (2001) 8.54
Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med (2008) 8.39
AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation (2006) 8.01
Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA (2009) 7.78
Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med (2010) 7.39
Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA (2009) 6.80
Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet (2008) 6.41
Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA (2010) 6.29
A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ (2009) 6.21
Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet (2005) 5.86
Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol (2008) 5.77
Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med (2005) 5.28
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation (2004) 4.56
Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet (2009) 4.31
Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood (2006) 3.49
Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J Thromb Haemost (2007) 3.38
Paraoxonase-1 is a major determinant of clopidogrel efficacy. Nat Med (2010) 3.32
Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J Am Coll Cardiol (2007) 3.20
Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. J Am Coll Cardiol (2008) 3.10
Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel. Am Heart J (2008) 3.05
Proton-pump inhibitors are associated with increased cardiovascular risk independent of clopidogrel use: a nationwide cohort study. Ann Intern Med (2010) 2.90
Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J Am Coll Cardiol (2007) 2.73
Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J Am Coll Cardiol (2006) 2.33
Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel. Thromb Haemost (2009) 2.09
The effect of CYP2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel: a possible mechanism for clopidogrel resistance. Clin Pharmacol Ther (2008) 2.04
Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysis. J Am Coll Cardiol (2010) 2.03
Review article: cytochrome P450 and the metabolism of proton pump inhibitors--emphasis on rabeprazole. Aliment Pharmacol Ther (1999) 1.98
Resistance to clopidogrel: a review of the evidence. J Am Coll Cardiol (2005) 1.98
Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention. Eur Heart J (2009) 1.92
Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST Study. J Am Coll Cardiol (2005) 1.81
Effect of cytochrome p450 polymorphisms on platelet reactivity after treatment with clopidogrel in acute coronary syndrome. Am J Cardiol (2008) 1.71
The common gene variants of CYP2C19 affect pharmacokinetics and pharmacodynamics in an active metabolite of clopidogrel in healthy subjects. J Thromb Haemost (2008) 1.62
Relation of cytochrome P450 2C19 loss-of-function polymorphism to occurrence of drug-eluting coronary stent thrombosis. Am J Cardiol (2009) 1.57
Influence of omeprazol on the antiplatelet action of clopidogrel associated to aspirin. J Thromb Haemost (2006) 1.51
Genetic variation in metabolizing enzyme and transporter genes: comprehensive assessment in 3 major East Asian subpopulations with comparison to Caucasians and Africans. J Clin Pharmacol (2010) 1.44
Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10 + 12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients. Pharmacogenet Genomics (2007) 1.43
Clopidogrel hyporesponsiveness and the FDA boxed warning: detection and management of patients with genetic polymorphisms. Am J Health Syst Pharm (2011) 1.40
Genetic polymorphism of cytochrome P450 2C19 in Mexican Americans: a cross-ethnic comparative study. Clin Pharmacol Ther (2006) 1.36
Initial assessment of clinical impact of a drug interaction between clopidogrel and proton pump inhibitors. J Am Coll Cardiol (2008) 1.34
Cytochrome P450 2C19*2 polymorphism and cardiovascular recurrences in patients taking clopidogrel: a meta-analysis. Pharmacogenomics J (2010) 1.25
ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. Am J Gastroenterol (2008) 1.21
Platelet function testing and implications for clinical practice. J Cardiovasc Pharmacol Ther (2009) 0.87
Clopidogrel resistance. Heart Lung Circ (2007) 0.84
Genetic causes of clopidogrel nonresponsiveness: which ones really count? Pharmacotherapy (2010) 0.83
Impact of genetic and acquired alteration in cytochrome P450 system on pharmacologic and clinical response to clopidogrel. Pharmacol Ther (2009) 0.80
Proton pump inhibitor and clopidogrel interaction: the case for watchful waiting. J Gastroenterol Hepatol (2010) 0.79
Concomitant use of clopidogrel and proton pump inhibitors or cimetidine after acute myocardial infarction would increase the risk of re-infarction. Am J Gastroenterol (2009) 0.76
Abnormal heart rate recovery on exercise in ankylosing spondylitis. Int J Cardiol (2013) 2.00
Aldosterone receptor antagonism induces reverse remodeling when added to angiotensin receptor blockade in chronic heart failure. J Am Coll Cardiol (2007) 1.73
Benefits of cardiac resynchronization therapy for heart failure patients with narrow QRS complexes and coexisting systolic asynchrony by echocardiography. J Am Coll Cardiol (2006) 1.70
Diastolic and systolic asynchrony in patients with diastolic heart failure: a common but ignored condition. J Am Coll Cardiol (2006) 1.62
Does prior percutaneous coronary intervention adversely affect early and mid-term survival after coronary artery surgery? JACC Cardiovasc Interv (2009) 1.61
May-Thurner syndrome in patients with cryptogenic stroke and patent foramen ovale: an important clinical association. Stroke (2009) 1.58
Effect of left ventricular lead concordance to the delayed contraction segment on echocardiographic and clinical outcomes after cardiac resynchronization therapy. J Cardiovasc Electrophysiol (2008) 1.54
Left atrial regional phasic strain, strain rate and velocity by speckle-tracking echocardiography: normal values and effects of aging in a large group of normal subjects. Int J Cardiol (2013) 1.52
Survival of elderly patients undergoing percutaneous coronary intervention for acute myocardial infarction complicated by cardiogenic shock. JACC Cardiovasc Interv (2009) 1.52
Alternatives to chronic warfarin therapy for the prevention of stroke in patients with atrial fibrillation. Int J Cardiol (2010) 1.50
Impact of reduction in early- and late-systolic functional mitral regurgitation on reverse remodelling after cardiac resynchronization therapy. Eur Heart J (2010) 1.50
Right ventricular long-axis response to different chronic loading conditions: its relevance to clinical symptoms. Int J Cardiol (2012) 1.50
Impact of concomitant heart failure on outcomes in patients undergoing percutaneous coronary interventions: analysis of the Melbourne Interventional Group registry. Eur J Heart Fail (2011) 1.41
Unusual case of recurrent renal artery stenosis: lessons to learn. Kidney Int (2008) 1.40
Long-term effect of bosentan therapy on cardiac function and symptomatic benefits in adult patients with Eisenmenger syndrome. J Card Fail (2012) 1.40
Renin-angiotensin-aldosterone system blockade for cardiovascular diseases: current status. Br J Pharmacol (2010) 1.39
Images in cardivascular medicine. Detection of large aneurysm of Vieussens' arterial ring after abnormal shadow on chest radiography. Circulation (2009) 1.24
Rho-kinase inhibition: a novel therapeutic target for the treatment of cardiovascular diseases. Drug Discov Today (2010) 1.24
Left atrial appendage closure with AMPLATZER cardiac plug for stroke prevention in atrial fibrillation: initial Asia-Pacific experience. Catheter Cardiovasc Interv (2011) 1.20
Left atrial appendage exclusion: state-of-the-art. Catheter Cardiovasc Interv (2010) 1.12
Subjects at risk of discontinuation of lipid-lowering agents: a 6-month cohort study among 12,875 patients in a chinese population. Clin Ther (2011) 1.10
Quantification of left ventricular regional myocardial function using two-dimensional speckle tracking echocardiography in healthy volunteers--a multi-center study. Int J Cardiol (2012) 1.08
Albumin levels predict survival in patients with heart failure and preserved ejection fraction. Eur J Heart Fail (2011) 1.07
Preclinical evaluation of a new left atrial appendage occluder (Lifetech LAmbre™ device) in a canine model. Int J Cardiol (2013) 0.97
The effect of intended duration of clopidogrel use on early and late mortality and major adverse cardiac events in patients with drug-eluting stents. Am Heart J (2009) 0.96
Impact of cardiac contractility modulation on left ventricular global and regional function and remodeling. JACC Cardiovasc Imaging (2009) 0.93
Effect of age and gender on left ventricular rotation and twist in a large group of normal adults--a multicenter study. Int J Cardiol (2012) 0.92
Role of warfarin pharmacogenetic testing in clinical practice. Pharmacogenomics (2010) 0.92
Images in cardiovascular medicine. Giant left circumflex coronary artery aneurysm with arteriovenous fistula to the coronary sinus. Circulation (2008) 0.90
Venous and arterial disease in inflammatory bowel disease. J Gastroenterol Hepatol (2013) 0.90
A novel multi-layer approach of measuring myocardial strain and torsion by 2D speckle tracking imaging in normal subjects and patients with heart diseases. Int J Cardiol (2009) 0.89
Are left ventricular diastolic function and diastolic asynchrony important determinants of response to cardiac resynchronization therapy? Am J Cardiol (2006) 0.89
The mystery of coronary artery spasm. Heart Lung Circ (2006) 0.87
Coil embolization of an iatrogenic coronary artery to cardiac vein fistula after rotational atherectomy. J Interv Cardiol (2008) 0.86
Percutaneous closure of patent foramen ovale for cryptogenic stroke: a meta-analysis of randomized controlled trials. Int J Cardiol (2013) 0.86
Marantic endocarditis presenting as recurrent arterial embolisation. Int J Cardiol (2007) 0.86
Measuring health related quality of life in coronary heart disease: the importance of feeling well. Int J Cardiol (2010) 0.86
Characterization of mid-term atrial geometrical and electrical remodeling following device closure of atrial septal defects in adults. Int J Cardiol (2012) 0.85
Quality of life after percutaneous coronary intervention in the elderly with acute coronary syndrome. Int J Cardiol (2010) 0.85
Current status of rho-associated kinases (ROCKs) in coronary atherosclerosis and vasospasm. Cardiovasc Hematol Agents Med Chem (2009) 0.85
Elevated rho-kinase activity as a marker indicating atherosclerosis and inflammation burden in polyvascular disease patients with concomitant coronary and peripheral arterial disease. Clin Cardiol (2013) 0.84
Contemporary outcomes in women undergoing percutaneous coronary intervention for acute coronary syndromes. Int J Cardiol (2010) 0.84
Comparison of angiotensin-converting enzyme inhibitor alone and in combination with irbesartan for the treatment of heart failure. Int J Cardiol (2007) 0.84
Smad7 inhibits angiotensin II-induced hypertensive cardiac remodelling. Cardiovasc Res (2013) 0.83
The value of admission HbA(1c) level in diabetic patients with acute coronary syndrome. Clin Cardiol (2011) 0.83
Relation of left ventricular systolic dyssynchrony in patients with heart failure to left ventricular ejection fraction and to QRS duration. Am J Cardiol (2008) 0.83
Diagnosis of cleft mitral valve using real-time 3-dimensional transesophageal echocardiography. Int J Cardiol (2013) 0.83
Deleterious effect of right ventricular apical pacing on left ventricular diastolic function and the impact of pre-existing diastolic disease. Eur Heart J (2011) 0.83
An armband wearable device for overnight and cuff-less blood pressure measurement. IEEE Trans Biomed Eng (2014) 0.82
Dabigatran etexilate versus warfarin as the oral anticoagulant of choice? A review of clinical data. Pharmacol Ther (2010) 0.82
Dabigatran compared with warfarin for stroke prevention with atrial fibrillation: experience in Hong Kong. Clin Cardiol (2012) 0.82
Tissue Doppler imaging--a sensible imaging option for the sensitive heart. Int J Cardiovasc Imaging (2006) 0.81
Predictors of survival after aortic valve replacement in patients with low-flow and high-gradient aortic stenosis. Eur J Heart Fail (2009) 0.81
Deficiency of Smad7 enhances cardiac remodeling induced by angiotensin II infusion in a mouse model of hypertension. PLoS One (2013) 0.81
Outcomes after percutaneous coronary intervention in contemporary Australian practice: insights from a large multicentre registry. Med J Aust (2008) 0.81
Transcatheter renal artery sympathetic denervation for resistant hypertension: an old paradigm revisited. Int J Cardiol (2012) 0.80
Bleeding of new oral anticoagulants for stroke prevention in atrial fibrillation: a meta-analysis of randomized controlled trials. Cardiovasc Drugs Ther (2013) 0.80
Attenuation of systolic blood pressure and pulse transit time hysteresis during exercise and recovery in cardiovascular patients. IEEE Trans Biomed Eng (2014) 0.80
Incremental prognostic value of combining left ventricular lead position and systolic dyssynchrony in predicting long-term survival after cardiac resynchronization therapy. Clin Sci (Lond) (2009) 0.80
Impact of genetic and acquired alteration in cytochrome P450 system on pharmacologic and clinical response to clopidogrel. Pharmacol Ther (2009) 0.80
Pharmacological and cellular therapies to prevent restenosis after percutaneous transluminal angioplasty and stenting. Cardiovasc Hematol Agents Med Chem (2008) 0.80
Proton pump inhibitor and clopidogrel interaction: the case for watchful waiting. J Gastroenterol Hepatol (2010) 0.79
Prevalence and determinants of left ventricular systolic dyssynchrony in patients with normal ejection fraction received right ventricular apical pacing: a real-time three-dimensional echocardiographic study. Eur J Echocardiogr (2009) 0.79
Prevalence and determinants of incomplete right atrial reverse remodeling after device closure of atrial septal defects. Am J Cardiol (2011) 0.79
Barriers to warfarin use for stroke prevention in patients with atrial fibrillation in Hong Kong. Clin Cardiol (2012) 0.79
Investigational devices for mitral regurgitation: state of the art. Expert Rev Med Devices (2011) 0.79
Risk and management of upper gastrointestinal bleeding associated with prolonged dual-antiplatelet therapy after percutaneous coronary intervention. Cardiovasc Revasc Med (2009) 0.79
Management of access site and systemic complications of percutaneous coronary and peripheral interventions. J Invasive Cardiol (2008) 0.79
Mean platelet volume levels predict pulmonary artery hypertension in patients with atrial septal defect. Acta Cardiol (2014) 0.79
Incremental value of global systolic dyssynchrony in determining the occurrence of functional mitral regurgitation in patients with left ventricular systolic dysfunction. Eur Heart J (2012) 0.79
Left atrial function assessed by tissue doppler imaging as a new predictor of cardiac events after non-ST-elevation acute coronary syndrome. Echocardiography (2012) 0.79
The clinical outcome of restricting drug-eluting stents to patients at highest risk of restenosis. EuroIntervention (2006) 0.79
Effect of age and heart rate on atrial mechanical function assessed by Doppler tissue imaging in healthy individuals. J Am Soc Echocardiogr (2006) 0.78
Correlates of carotid stenosis in patients undergoing coronary artery bypass grafting--a case control study. Vasc Med (2009) 0.78
Wearable cuff-less PTT-based system for overnight blood pressure monitoring. Conf Proc IEEE Eng Med Biol Soc (2013) 0.78
LV mechanical dyssynchrony in heart failure with preserved ejection fraction complicating acute coronary syndrome. JACC Cardiovasc Imaging (2011) 0.78
Renal artery revascularization: collaborative approaches for specialists. Adv Chronic Kidney Dis (2008) 0.78
Chinese translation and validation of the Walking Impairment Questionnaire in patients with peripheral artery disease. Vasc Med (2011) 0.78
Changes of ventricular and peripheral performance in patients with heart failure and normal ejection fraction: insights from ergometry stress echocardiography. Eur J Heart Fail (2014) 0.78
Right ventricular stunning in inferior myocardial infarction. Int J Cardiol (2008) 0.77
Role of real time three-dimensional transesophageal echocardiography in guidance of interventional procedures in cardiology. Heart (2010) 0.77
Enhanced detection of patent foramen ovale by systematic transthoracic saline contrast echocardiography. Int J Cardiol (2010) 0.77
The no-reflow phenomenon in the coronary circulation. Cardiovasc Hematol Agents Med Chem (2009) 0.77
Acute effects of right ventricular apical pacing on left atrial remodeling and function. Pacing Clin Electrophysiol (2012) 0.77
Cardiovascular medication use following percutaneous coronary intervention: the Australian experience. Cardiovasc Ther (2014) 0.77
Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in patients with atrial fibrillation--a real patient data analysis in a Hong Kong teaching hospital. Clin Cardiol (2013) 0.77
Novel platelet ADP P2Y12 inhibitors in the treatment of acute coronary syndrome. Cardiovasc Ther (2011) 0.77